Swine Vaccines Market Size and Share
Swine Vaccines Market Analysis by Mordor Intelligence
The swine vaccines market is valued at USD 1.81 billion in 2025 and is forecast to reach USD 2.32 billion by 2030, advancing at a 5.09% CAGR. Strong growth reflects a permanent shift from treating outbreaks to preventing them, as biosecurity rules tighten and producers protect herds that are more valuable than ever. Vaccination already offsets the USD 1.2 billion lost each year to porcine reproductive and respiratory syndrome, turning immunization from an optional cost into standard risk control. Technology disruption reinforces expansion: RNA particle platforms cut custom vaccine lead times to 12–16 weeks, while gene-edited pigs resistant to PRRS broaden the toolbox beyond traditional antigens. Regionally, North America holds 38.45% 2024 revenue on the back of advanced veterinary infrastructure, whereas Asia-Pacific posts the fastest CAGR at 6.23% as producers rebuild after African swine fever. Inactivated products stay ahead with 46.77% share, but recombinant lines grow at 6.02% as buyers favor safer DIVA-compliant options.
Key Report Takeaways
- By product type, inactivated formulations led with 46.77% of the swine vaccines market share in 2024; recombinant platforms are set to expand at a 6.02% CAGR through 2030.
- By disease type, classical swine fever accounted for 40.22% of the swine vaccines market size in 2024, while swine influenza is projected to climb at a 5.98% CAGR to 2030.
- By route of administration, injectable vaccines held 76.34% of 2024 revenue; intranasal delivery is forecast to grow at a 6.12% CAGR over 2025–2030.
- By geography, North America captured 38.45% revenue in 2024; Asia-Pacific is the fastest-growing region at 6.23% CAGR through 2030.
Global Swine Vaccines Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Government Initiatives Toward Swine-Flu Management & Higher Public Awareness | +0.8% | Global, with strongest impact in Asia-Pacific and Europe | Medium term (2-4 years) |
Growth In R&D Outlays for Novel Vaccine Platforms | +1.2% | North America & EU leading, spill-over to APAC | Long term (≥ 4 years) |
Escalating Global Pork Consumption & Intensifying Bio-Security Mandates | +1.0% | Global, particularly emerging markets | Medium term (2-4 years) |
Rapid-Response Autogenous/RNA Platforms Shorten Time-To-Immunity | +0.9% | North America & EU core markets | Short term (≤ 2 years) |
AI-Driven Herd Analytics Enable Precision Vaccination & Lower TCO | +0.7% | North America, early adoption in EU and Asia-Pacific | Long term (≥ 4 years) |
Trade-Oriented Shift Toward DIVA-Compliant Vaccines | +0.6% | Global, with emphasis on export-oriented regions | Medium term (2-4 years) |
Source: Mordor Intelligence
Government Initiatives Toward Swine-Flu Management & Higher Public Awareness
Mandatory health programs convert voluntary actions into structured prevention plans. The proposed U.S. Swine Health Improvement Plan creates national rules for tracking African swine fever and classical swine fever, rewarding farms that vaccinate [1]Animal and Plant Health Inspection Service, "APHIS Announces Proposed Rule to Establish U.S. Swine Health Improvement Plan as a Federal Regulatory Program," aphis.usda.gov. The Philippines issued 10,000 ASF doses under state supervision to test efficacy and build public trust. Taiwan achieved disease-free status for three major swine infections after years of coordinated campaigns, proving that clear government-industry alignment can lower routine vaccination needs. These successes reinforce positive feedback loops: as outbreaks fall, producers keep investing in vaccines to protect market access. In parallel, the incentive to comply grows because vaccinated herds earn smoother domestic movement and export clearance.
Growth in R&D Outlays for Novel Vaccine Platforms
Investment is shifting toward platforms that close gaps in speed and strain coverage. Merck earmarked USD 895 million for Kansas facilities that underpin its RNA particle line, Sequivity. The University of Pittsburgh’s trans-amplifying mRNA work shows similar immunity with far less active ingredient, lowering cost per dose. USDA grants fund self-amplifying mRNA projects against ASF and classical swine fever, signaling official support for next-gen approaches. Start-ups push the frontier too; Aptamer Group licensed nanobody adjuvants to boost swine responses. Collectively, rising R&D spend accelerates roll-out of vaccines that are easier to tailor and more economical to scale.
Escalating Global Pork Consumption & Intensifying Biosecurity Mandates
Higher protein demand collides with stronger safety rules, keeping the swine vaccines market on a persistent growth path. U.S. output is set to rise 1.7% in 2025 even as PRRS continues to drain USD 1.2 billion each year, affirming vaccination as insurance against lost revenue. Thailand’s pork consumption is climbing 3.91% annually, driving feed giants such as Cargill to boost capacity and prompting producers to vaccinate aggressively. European foot-and-mouth disease flare-ups forced immediate trade restrictions, highlighting how disease events turn preventive immunization into a compliance requirement. China’s post-ASF herd rebuild further underlines the link between vaccination and stable supply [2]United States Department of Agriculture, "Livestock and Products Annual," apps.fas.usda.gov. As markets liberalize, exporters rely on DIVA-compliant products that keep borders open, reinforcing demand.
Rapid-Response Autogenous/RNA Platforms Shorten Time-To-Immunity
New platforms tackle the core problem of viral evolution outpacing conventional development. Merck’s Sequivity delivers farm-specific vaccines in 12–16 weeks by using RNA particles matched to local pathogen sequences. USDA cleared the platform to pair with Microsol Diluvac Forte, extending protection length without adding months of lead time. Canada’s rules for autogenous biologics let veterinarians order custom batches for urgent threats. Self-amplifying mRNA models need less material yet trigger strong immunity, lowering production cost in emergency campaigns. Producers gain the agility to vaccinate sooner and more precisely, limiting losses during the critical early weeks of an outbreak.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
High Cold-Chain Costs & Risk of Adverse Reactions | -0.9% | Global, particularly challenging in developing regions | Medium term (2-4 years) |
Lengthy, Stringent Regulatory Approval Cycles | -0.7% | Global, with varying intensity by region | Long term (≥ 4 years) |
Viral Genotype Drift Outpacing Vaccine Strain Updates | -0.8% | Global, with highest impact in Asia-Pacific and Europe | Short term (≤ 2 years) |
Budget Diversion To Antibiotic-Free Certification Programs | -0.5% | North America & EU primarily, expanding to export-oriented farms globally | Medium term (2-4 years) |
Source: Mordor Intelligence
High Cold-Chain Costs & Risk of Adverse Reactions
Temperature-controlled logistics add sizeable expenses, particularly where power grids are unreliable. Freeze-drying research on African swine fever vaccine kept potency for 1 year at 4 °C, but adoption is pending broader field proof [3]Nallely Espinoza, "Lyophilization of ASFV vaccine candidate ASFV-G-ΔI177L offers long term stability," Scientific Reports, nature.com. Freeze-preventive cold boxes evaluated in Nepal solved freezing but became heavier and harder to transport over rough terrain. Vietnam’s smart-pig trials found vaccination bills between USD 4.7 and 9 per pig, with chilling and handling making up a major share. FAO manuals emphasize that broken cold chains undermine efficacy, leading to revaccination costs and liability concerns. These factors slow uptake among smallholders who operate on thin margins despite clear disease-control benefits.
Lengthy, Stringent Regulatory Approval Cycles
Comprehensive safety dossiers protect animal health but stretch timelines and costs. FDA biologics data from 2024 show multi-year paths from investigational studies to licensure, a hurdle that favors incumbents with deep regulatory teams. Merck’s PORCILIS PCV M Hyo ID cleared the European Medicines Agency only after an extended review covering multiple member states. The Philippines’ ASF pilot required government-run phases before wider use, delaying commercial roll-out even though initial results were positive. For exporters, USDA certification must also match rules in each importing country, adding another layer. Protracted approvals limit the agility needed to counter fast-moving viral threats and raise the capital bar for start-ups targeting the swine vaccines market.
Segment Analysis
By Product: Recombinant Platforms Drive Innovation
In 2024, inactivated vaccines claimed 46.77% of the swine vaccines market share thanks to decades of field success and straightforward production. Recombinant lines post the fastest 6.02% CAGR to 2030 as buyers prize DIVA features that keep trade channels open. Attenuated live options remain in use for robust cellular immunity, though safety rules curtail volumes in high-density farms. Recombinant tools also ease updates when viral genotypes drift beyond current strain panels. The swine vaccines market size for recombinant products is positioned to accelerate as regulators gain experience with platform approvals.
The mRNA wave underscores this tilt toward precision. Sequivity’s RNA particles, ready in 12–16 weeks, contrast sharply with classical antigen culture timelines. PEDV spike-mRNA prototypes already trigger stronger responses than inactivated benchmarks. Meanwhile, oral and nanobody-based ideas broaden the “Others” bucket by tackling ease-of-use and stronger mucosal immunity. Together these shifts indicate that future sales will track how quickly each supplier can update antigens while keeping pricing inside producer budgets.
Note: Segment shares of all individual segments available upon report purchase
By Disease Type: Classical Swine Fever Dominance Faces Influenza Challenge
Classical swine fever vaccines contributed 40.22% of 2024 revenue as the disease carries heavy trade and mortality penalties. Live-attenuated FlagT4G shows how efficacy can coexist with DIVA tags, supporting eradication drives and verification testing. Swine influenza formulations grow at 5.98% CAGR because zoonotic risks and rapid viral drift push regular updates. Studies in China link vaccination pressure to faster H1N1 evolution, proving that constant surveillance and reformulation are essential.
Porcine parvovirus products deliver steady returns by safeguarding litter sizes, while circovirus vaccines shift to bivalent blends covering PCV2 and PCV3 variants. Research groups fast-track ASF candidates now that farm trials can replicate natural infection. The swine vaccines industry expects more disease-specific platforms that tailor immunity without compromising diagnostics.
By Route of Administration: Injectable Dominance Meets Intranasal Innovation
Injectable delivery accounted for 76.34% of 2024 sales, reflecting veterinarian familiarity and precise dosing. Intradermal products such as PORCILIS PCV M Hyo ID reduce needle volume and stress but keep the core injection model. The swine vaccines market size for intranasal routes is rising on a 6.12% trajectory as producers seek lower labor and stronger mucosal defense. Influenza-vectored intranasal trials show protection at the pathogen’s entry point.
Oral sprays and feed-based carriers serve niche mass-piglet programs, yet stability challenges limit their spread. Needle-free jet devices trim injury risk and enhance throughput. As AI monitoring becomes common, farms can match precise respiratory scores with intranasal boosters, raising the likelihood that alternative routes will chip away at injectable dominance.

Note: Segment shares of all individual segments available upon report purchase
Geography Analysis
North America generated 38.45% of 2024 revenue, supported by strict biosecurity and well-funded producers willing to pay for autogenous and RNA solutions. Federal plans such as the Swine Health Improvement Plan formalize traceability and vaccination compliance. Canada’s USD 57.5 million vaccine bank for foot-and-mouth disease signals public investment in rapid response. The swine vaccines market size in North America is also buoyed by a deep cold-chain and dense veterinary service network that ensures uptake.
Asia-Pacific registers the fastest 6.23% CAGR as the region rebuilds inventories after ASF. China’s restocking proves that coordinated vaccination, enhanced genetics, and modern barns stabilize supply. The Philippines runs supervised ASF vaccination using a Vietnamese-developed candidate, testing efficacy under field stress. Vietnam’s smart-farming push prices vaccination between USD 4.7 and 9 per pig and demonstrates willingness to pay when productivity gains are clear. Thailand’s rising pork appetite compounds momentum.
Europe, the Middle East and Africa, and South America offer varied prospects. Europe’s FMD cases in 2024 forced emergency vaccine orders that protected export licenses. The bloc’s rigorous approval process slows new entrants yet builds end-user confidence, supporting steady demand for premium recombinant products. Middle East and African markets struggle with cold-chain gaps, inviting thermostable formulations. South America’s export players adopt DIVA vaccines to secure market access, expanding volume while raising bar for compliance among domestic peers.

Competitive Landscape
The swine vaccines market shows moderate concentration. Zoetis, Merck Animal Health, and Boehringer Ingelheim anchor the top tier with broad portfolios and global distribution. Zoetis markets more than 300 animal-health products and maintains deep technical support, which shields share even as niche rivals appear. Merck leverages Sequivity to target precision needs and is scaling output through a USD 895 million Kansas build-out. Boehringer’s Dynamic Pig Health program integrates ten FLEX vaccines with gut-health brands to cover respiratory and enteric threats in one protocol.
Mid-tier firms broaden capabilities through acquisitions. Phibro spent USD 350 million on Zoetis’ medicated feed additive assets, pairing nutrition and vaccine lines to create bundled health solutions. Technology specialists focus on narrow breakthroughs: mRNA start-ups iterate immunogens in weeks, adjuvant innovators supply nanobody boosters, and software firms turn sensor data into vaccination-timing alerts. Larger incumbents respond by forming research pacts or buying these niche skills outright.
Competition now hinges on five levers: platform speed, strain-update agility, cold-chain simplicity, combined respiratory-enteric coverage, and digital integration. Firms that align all five command pricing power, while laggards face commoditization in basic inactivated products. The swine vaccines market continues to reward scale economies along with differentiated science.
Swine Vaccines Industry Leaders
-
Merck & Co., Inc.
-
Elanco
-
Boehringer Ingelheim International GmbH
-
Zoetis Inc.
-
Ceva Sante Animale
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- June 2025: EMA issued a positive opinion for Biobhyo to prevent swine dysentery caused by Brachyspira hyodysenteriae.
- May 2025: The Pirbright Institute and The Vaccine Group began African swine fever vaccine challenge trials using a virulent field strain.
- February 2025: Virbac introduced a neonatal piglet diarrhea vaccine in Europe.
- March 2024: Merck Animal Health secured USDA approval for Sequivity paired with Microsol Diluvac Forte to extend immunity in custom RNA particle vaccines.
Global Swine Vaccines Market Report Scope
As per the scope of the report, swine vaccines are generally given to pigs and contain antigens from bacteria, viruses, parasites, or bacterial toxins. It helps to promote an immune response in pigs, which protects against natural infection from which the vaccine has been derived. The swine vaccines market is segmented by product (inactivated vaccines, attenuated live vaccines, recombinant vaccines, and others), disease type (classical swine fever, porcine parvovirus, swine influenza, and others), and geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD) for the above segments.
By Product | Inactivated Vaccines | ||
Attenuated Live Vaccines | |||
Recombinant Vaccines | |||
Others | |||
By Disease Type | Classical Swine Fever (CSF) | ||
Porcine Parvovirus | |||
Swine Influenza | |||
Porcine Circovirus (PCV) | |||
Others | |||
By Route of Administration | Injectables | ||
Intranasal | |||
Oral | |||
By Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Inactivated Vaccines |
Attenuated Live Vaccines |
Recombinant Vaccines |
Others |
Classical Swine Fever (CSF) |
Porcine Parvovirus |
Swine Influenza |
Porcine Circovirus (PCV) |
Others |
Injectables |
Intranasal |
Oral |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia-Pacific | China |
Japan | |
India | |
Australia | |
South Korea | |
Rest of Asia-Pacific | |
Middle East and Africa | GCC |
South Africa | |
Rest of Middle East and Africa | |
South America | Brazil |
Argentina | |
Rest of South America |
Key Questions Answered in the Report
What is the current size of the swine vaccines market?
The market stands at USD 1.81 billion in 2025 and is projected to grow steadily to USD 2.32 billion by 2030.
Which region leads swine vaccine revenue today?
North America holds 38.45% of global revenue owing to advanced veterinary infrastructure and strict biosecurity rules.
Which product segment is growing the fastest?
Recombinant vaccines record the highest 6.02% CAGR through 2030 as producers adopt safer, DIVA-ready platforms.
Why are intranasal vaccines gaining attention?
They stimulate local respiratory immunity, cut labor time, and are forecast to expand at 6.12% CAGR over 2025–2030.
What are the main restraints affecting market growth?
High cold-chain costs in developing regions and lengthy regulatory approvals together shave roughly 1.6 percentage points off potential CAGR.
How are rapid-response RNA platforms changing the landscape?
Technologies such as Sequivity cut vaccine customization cycles to 12–16 weeks, enabling quicker containment of new viral strains.
Page last updated on: July 1, 2025